The Korean journal of internal medicine

  • 제26권3호
  • /
  • Pages.328-339
  • /
  • 2011
  • /
  • 1226-3303(pISSN)
  • /
  • 2005-6648(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

Acute Lymphoblastic Leukemia in Elderly Patients: A Single Institution's Experience

  • Shin, Dong-Yeop (Department of Internal Medicine, Seoul National University Hospital) ;
  • Kim, In-Ho (Department of Internal Medicine, Seoul National University Hospital) ;
  • Kim, Ki-Hwan (Department of Internal Medicine, Seoul Municipal Boramae Hospital) ;
  • Choi, You-Nak (Department of Internal Medicine, Seoul National University Hospital) ;
  • Beom, Seung-Hoon (Department of Internal Medicine, Seoul National University Hospital) ;
  • Yang, Yae-Won (Department of Internal Medicine, Seoul National University Hospital) ;
  • Lim, Yoo-Joo (Department of Internal Medicine, Seoul National University Hospital) ;
  • Lee, Eun-Young (Department of Internal Medicine, Seoul National University Hospital) ;
  • Lee, June-Koo (Department of Internal Medicine, Seoul National University Hospital) ;
  • Kim, Ji-Yeon (Department of Internal Medicine, Seoul National University Hospital) ;
  • Kim, Hyun-Kyung (Department of Laboratory Medicine, Seoul National University College of Medicine) ;
  • Yoon, Sung-Soo (Department of Internal Medicine, Seoul National University Hospital) ;
  • Lee, Dong-Soon (Department of Laboratory Medicine, Seoul National University College of Medicine) ;
  • Park, Seon-Yang (Department of Internal Medicine, Seoul National University Hospital) ;
  • Kim, Byoung-Kook (Department of Internal Medicine, Seoul National University Hospital)
  • 발행 : 2011.09.01
⟨ 이전 논문 다음 논문 ⟩

초록

Background/Aims: We investigated the clinical characteristics and prognosis of elderly patients with acute lymphoblastic leukemia (ALL). Methods: We reviewed the clinical data, laboratory findings, bone marrow findings, and cytogenetic analysis of elderly patients (${\geq}$ 60 years) with ALL, and data of an additional 101 younger adult patients (< 60 years) with ALL were reviewed for comparison. Results: Twenty-six elderly patients (${\geq}$ 60 years) and 101 younger adult patients (< 60 years) with ALL were retrospectively enrolled. The median follow-up duration was 6.0 months (range, 0.4 to 113.2) in the elderly patients and 21.7 months (range, 1.0 to 122.7) in the adult patients. In total, 34.6% (9 patients) of the elderly patients and 24.8% (25 patients) of the adult patients had Philadelphia chromosome positive ALL. The overall complete remission (CR) rate was much higher in the younger than in the elderly patients (94.1% vs. 57.7%, p < 0.001). The median overall survival (OS) of the younger patients (< 60 years) was 26.3 months, whereas that of the elderly patients (${\geq}$ 60 years) was 10.3 months (p = 0.003). In the elderly patients with ALL, T cell lineage and the presence of lymphadenopathy were significant prognostic factors for OS in a univariate analysis (p = 0.033 and 0.041, respectively). Conclusions: The outcomes of Korean elderly patients with ALL were poor, and the shorter OS was mainly due to the low CR rate. T-cell lineage and the presence of lymphadenopathy were significant prognostic factors in Korean elderly patients with ALL.

키워드

참고문헌

  1. Baker MA. The management of leukaemia in the elderly. Baillieres Clin Haematol 1987;1:427-448. https://doi.org/10.1016/S0950-3536(87)80008-2
  2. Delannoy A, Ferrant A, Bosly A, et al. Acute lymphoblastic leukemia in the elderly. Eur J Haematol 1990;45:90-93.
  3. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program [Internet]. Bethesda, MD: National Cancer Institute, c2008 [cited 2008 Jun 20]. Available from: http://www.seer.cancer.gov/statfacts/html/alyl.html.
  4. Thomas X, Olteanu N, Charrin C, Lheritier V, Magaud JP, Fiere D. Acute lymphoblastic leukemia in the elderly: The Edouard Herriot Hospital experience. Am J Hematol 2001;67:73-83. https://doi.org/10.1002/ajh.1083
  5. Robak T, Szmigielska-Kaplon A, Wrzesien-Kus A, et al. Acute lymphoblastic leukemia in elde rly: the Polish Adult Leukemia Group (PALG) experience. Ann Hematol 2004;83:225-231. https://doi.org/10.1007/s00277-003-0808-9
  6. Virgilio JF, Moscinski LC, Ballester OF, et al. Acute lymphocytic leukemia (ALL) in elderly patients. Hematol Oncol 1993;11:121-126. https://doi.org/10.1002/hon.2900110302
  7. Kantarjian HM, O'Brien S, Smith T, et al. Acute lymphocytic leukaemia in the elderly: characteristics and outcome with the vincristine-adriamycin-dexamethasone (VAD) regimen. Br J Haematol 1994;88:94-100. https://doi.org/10.1111/j.1365-2141.1994.tb04982.x
  8. Spath-Schwalbe E, Heil G, Heimpel H. Acute lymphoblastic leukemia in patients over 59 years of age: experience in a single center over a 10-year period. Ann Hematol 1994;69:291-296. https://doi.org/10.1007/BF01696557
  9. Ferrari A, Annino L, Crescenzi S, Romani C, Mandelli F. Acute lymphoblastic leukemia in the elderly: results of two different treatment approaches in 49 patients during a 25-year period. Leukemia 1995;9:1643-1647.
  10. Bassan R, Di Bona E, Lerede T, et al. Age-adapted moderatedose induction and flexible outpatient postremission therapy for elderly patients with acute lymphoblastic leukemia. Leuk Lymphoma 1996;22:295-301. https://doi.org/10.3109/10428199609051761
  11. Delannoy A, Sebban C, Cony-Makhoul P, et al. Age-adapted induction treatment of acute lymphoblastic leukemia in the elderly and assessment of maintenance with interferon combined with chemotherapy: a multicentric prospective study in forty patients. French Group for Treatment of Adult Acute Lymphoblastic Leukemia. Leukemia 1997;11:1429-1434. https://doi.org/10.1038/sj.leu.2400780
  12. Shin HC, Na II, Yun T, et al. Acute myelogenous leukemia in the elderly (>or=60): retrospective study of 115 patients. Korean J Med 2006;70:196-206.
  13. Boucheix C, David B, Sebban C, et al. Immunophenotype of adult acute lymphoblastic leukemia, clinical parameters, and outcome: an analysis of a prospective trial including 562 tested patients (LALA87). French Group on Therapy for Adult Acute Lymphoblastic Leukemia. Blood 1994;84:1603-1612.
  14. Linker CA, Levitt LJ, O'Donnell M, Forman SJ, Ries CA. Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: a follow-up report. Blood 1991;78:2814-2822.
  15. Mandelli F, Annino L, Rotoli B. The GIMEMA ALL 0183 trial: analysis of 10-year follow-up. GIMEMA Cooperative Group, Italy. Br J Haematol 1996;92:665-672. https://doi.org/10.1046/j.1365-2141.1996.00394.x
  16. Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000;18:547-561. https://doi.org/10.1200/JCO.2000.18.3.547
  17. Huh HJ, Park CJ, Jang S, et al. Prognostic significance of multidrug resistance gene 1 (MDR1), multidrug resistancerelated protein (MRP) and lung resistance protein (LRP) mRNA expression in acute leukemia. J Korean Med Sci 2006;21:253-258. https://doi.org/10.3346/jkms.2006.21.2.253
  18. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997;89:3323-3329.
  19. Taylor PR, Reid MM, Proctor SJ. Acute lymphoblastic leukaemia in the elderly. Leuk Lymphoma 1994;13:373-380. https://doi.org/10.3109/10428199409049625
  20. Kantarjian H, Thomas D, O'Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a doseintensive regimen, in adult acute lymphocytic leukemia. Cancer 2004;101:2788-2801. https://doi.org/10.1002/cncr.20668
  21. Secker-Walker LM, Prentice HG, Durrant J, Richards S, Hall E, Harrison G. Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA. MRC Adult Leukaemia Working Party. Br J Haematol 1997;96:601-610. https://doi.org/10.1046/j.1365-2141.1997.d01-2053.x
  22. Larson RA, Dodge RK, Linker CA, et al. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood 1998;92:1556-1564.
  23. Delannoy A, Cazin B, Thomas X, et al. Treatment of acute lymphoblastic leukemia in the elderly: an evaluation of interferon alpha given as a single agent after complete remission. Leuk Lymphoma 2002;43:75-81. https://doi.org/10.1080/10428190210180
  24. Bao L, Gross SA, Ryder J, et al. Adult precursor B lymphoblastic leukemia in Shanghai, China: characterization of phenotype, cytogenetics and outcome for 137 consecutive cases. Int J Hematol 2009;89:431-437. https://doi.org/10.1007/s12185-009-0283-8
  25. Westbrook CA, Hooberman AL, Spino C, et al. Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762). Blood 1992;80:2983-2990.
  26. Thomas X, Thiebaut A, Olteanu N, et al. Philadelphia chromosome positive adult acute lymphoblastic leukemia: characteristics, prognostic factors and treatment outcome. Hematol Cell Ther 1998;40:119-128.
  27. Gleissner B, Gökbuget N, Bartram CR, et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 2002;99:1536-1543. https://doi.org/10.1182/blood.V99.5.1536
  28. Appelbaum FR. Impact of age on the biology of acute leukemia [Internet]. 2005 ASCO Annual Meeting; 2005 [cited 2011 Jul 20]. Available from: http://www.asco.org/ASCOv2/Home/Education%20&%20Training/Educational%20Book/PDF%20Files/2005/2005edbookleuk02.pdf.
  29. Moorman AV, Harrison CJ, Buck GA, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood 2007;109:3189-3197. https://doi.org/10.1182/blood-2006-10-051912
  30. Jang SN, Kim DH. Trends in the health status of older Koreans. J Am Geriatr Soc 2010;58:592-598. https://doi.org/10.1111/j.1532-5415.2010.02744.x
  31. Nout RA, Fiets WE, Struikmans H, Rosendaal FR, Putter H, Nortier JW. The in- or exclusion of non-breast cancer related death and contralateral breast cancer significantly affects estimated outcome probability in early breast cancer. Breast Cancer Res Treat 2008;109:567-572. https://doi.org/10.1007/s10549-007-9681-x

피인용 문헌

  1. Recent Advancements of Bortezomib in Acute Lymphocytic Leukemia Treatment vol.129, pp.4, 2013, https://doi.org/10.1159/000345260
  2. Elderly acute lymphoblastic leukemia: a Mayo Clinic study of 124 patients vol.60, pp.4, 2011, https://doi.org/10.1080/10428194.2018.1509318